Exane Derivatives Atea Pharmaceuticals, Inc. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Exane Derivatives holds 78 shares of AVIR stock, worth $265. This represents 0.0% of its overall portfolio holdings.
Number of Shares
78
Previous 78
-0.0%
Holding current value
$265
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AVIR
# of Institutions
112Shares Held
52.4MCall Options Held
900Put Options Held
126K-
Black Rock Inc. New York, NY9.12MShares$31 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN6.65MShares$22.6 Million13.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.44MShares$18.5 Million0.79% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.85MShares$16.5 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.61MShares$15.7 Million1.31% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $283M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...